CtDNA levels after neoadjuvant therapy may predict breast cancer recurrence better than pathologic complete response.
Saved in:
| Title: | CtDNA levels after neoadjuvant therapy may predict breast cancer recurrence better than pathologic complete response. |
|---|---|
| Source: | Pharma Business Week. 1/27/2026, pN.PAG-N.PAG. 1p. |
| Database: | Business Source Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
